Communiqués Recce Pharmaceuticals Ltd

Actions

RCE

AU000000RCE5

Produits pharmaceutiques

Marché Fermé - Australian S.E. 07:58:17 14/09/2026			Varia. 5j.	Varia. 1 janv.
0,3500 ^AUD	-1,41 %		-5,41 %	-46,15 %

31/08	Recce Pharmaceuticals Ltd publie ses résultats annuels pour l'exercice clos le 30 juin 2026	CI
31/08	Recce Pharmaceuticals Ltd : l'auditeur exprime des doutes sur la 'continuité de l'exploitation'	CI

Communiqués

23/04/25	Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections	AQ
10/04/25	Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders	AQ
27/02/25	Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives	AQ
19/02/25	Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway	AQ
22/01/25	Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections	AQ
10/12/24	Recce Pharmaceuticals Receives Approval from Indonesia’s Drug and Food Authority for Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections	AQ
27/11/24	Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives	AQ
12/11/24	Recce Pharmaceuticals Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections	AQ
06/11/24	Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections	AQ
31/10/24	Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical Trial	AQ
10/10/24	Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections	AQ
06/08/24	Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan	AQ
16/07/24	Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel	AQ
10/07/24	Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii	AQ
01/07/24	Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327	AQ
25/06/24	Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections	AQ
20/06/24	Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development	AQ
12/06/24	Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial	AQ
05/06/24	Recce Pharmaceuticals' synthetic approach to combatting AMR	AQ
17/05/24	Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial	AQ
16/05/24	Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial	AQ
13/05/24	Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study	AQ
07/05/24	Recce Pharmaceuticals completes global patent portfolio	AQ
30/04/24	Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	AQ
17/04/24	Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)	AQ